EXPERIENCE OF TREATMENT WITH DIRECT-ACTING ANTIVIRAL DRUGS IN PATIENTS WITH CIRRHOSIS AT THE OUTCOME OF CHRONIC HEPATITIS C


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To evaluate the efficiency and safety of 12-week therapy with paritaprevir/ritonavir/ombitasvir and dasabuvir in patients with cirrhosis at the outcome of genotype 1b chronic hepatitis C. Subjects and methods. The study included 12 patients with classes A and B cirrhosis who had previously untreated or failed to respond to therapy with IFN-containing regimens. All the patients received paritaprevir/ritonavir/ombitasvir (75/50/12.5 mg) 2 tablets once daily and dasabuvir (250 mg) 1 tablet twice daily for 12 weeks. Results. All the 12 patients completed a full therapy cycle. A sustained virologie response was obtained in all the patients at 12 and 24 weeks after treatment completion The most common adverse events were weakness (33%) and headache (33%). Conclusion. The results of therapy with paritaprevir/ritonavir/ombitasvir and dasabuvir allow it to be regarded as highly effective and safe for patients with HCV-related cirrhosis.

Full Text

Restricted Access

About the authors

I. M KHAERTYNOVA

Email: i.khaertynova@gmail.com
Kazan State Medical Academy, Branch, Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia Kazan, Russia

Yu. M SOZINOVA

Email: sozin131@mail.ru
Prof. A.F. Agafonov Republican Clinical Infectious Diseases Hospital Kazan, Russia

N. V GALEEVA

Email: Nelli_04@mail.ru
Prof. A.F. Agafonov Republican Clinical Infectious Diseases Hospital Kazan, Russia

Elza G. GAIFULLINA

Email: elsagaj@yandex.ru
Kazan State Medical Academy, Branch, Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia Kazan, Russia

Yu. R URMANCHEEVA

Email: NeHi_04@mail.ru
Prof. A.F. Agafonov Republican Clinical Infectious Diseases Hospital Kazan, Russia

M. R GATAULLIN

Email: Gataullin.Marat@tatar.ru
Prof. A.F. Agafonov Republican Clinical Infectious Diseases Hospital Kazan, Russia

References

  1. Guidelines for the screening, care and treatment of persons with hepatitis C infections. http://www.who.int/hiv/pub/ hepatitis/ hepatitis-c- guidelines/en/
  2. Пименов Н.Н., Вдовин А.В., Комарова С.В., Мамонова Н.А., Чуланов В.П., Покровский В.И. Актуальность и перспективы внедрения в России единого федерального регистра больных вирусными гепатитами В и С. Тер. архив 2013; (11): 4-9. Pimenov N.N., Vdovin A.V., Komarova S.V., Mamonova N.A., Chulanov V.P., Pokrovskij V.I. [The relevance and prospects of introducing a uniform federal register of patients with viral hepatitis B and C in Russia]. Terapevticheskij Arhiv 2013; (11): 4-9. (In Russ.).
  3. Brown R.S. Jr. Hepatitis C and liver transplantation. Nature 2005; 436(7053): 973-8.
  4. Mühlberger N., Schwarzer R., Lettmeier B., Sroczynski G., Zeuzem S., Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009; (9): 34.
  5. Tholey D.M., Ahn J. Impact of hepatitis C Virus Infection on Hepatocellular Carcinoma. Gastroenterol. Clin. North Am. 2015; 44(4): 761-73.
  6. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: 237-44.
  7. Бакулин И.Г., Сандлер Ю.Г. Цирроз печени: что нового в лечении. Эффективная фармакотерапия 2014; 43: 42-50. Bakulin I.G., Sandler Yu.G. [Liver oirrhosis: what”s new in treatment]. Еffektivmya Farmakoterapiya 2014; 43: 42-50. (In Russ.).
  8. Бурневич Э.З., Щаницына С.Е. Противовирусная терапия хронического гепатита С, основанная на интерфероне-а: закономерности и принципы. Клиническая фармакология и терапия 2016; (1): 8-13. Burnevich Ye.Z., Shhanicyna S.E. [Antiviral therapy of chronic hepatitis C, based on interferon-а: patterns and principles]. Klinicheskaya Farmakologiya i Terapiya 2016; (1): 8-13. (In Russ.).
  9. Smith-Palmer J., Cerri K., Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect. Dis. 2015; 15(19): 2013-19.
  10. Forns X., Navasa M., Rodes J. Treatment of HCV infection in patients with advanced cirrhosis. Hepatology 2004; 40: 498.
  11. Iacobellis A., Ippolito A., Andriulli A. Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. World J. Gastroenterol. 2008; 14(42): 6467-72.
  12. Iacobellis A., Andriulli A. Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection. Expert Opin. Pharmacother. 2009; (10): 1929-38.
  13. Poordad F., Hezode C., Trinh R., Kowdley K.V., Zeuze m S., Agarwal K., Shiffman M.L., Wedemeyer H., Berg T., Yoshida E.M., Forns X., Lovell S.S., Da SilvaTillmann B., Collins C.A., Campbell A.L., Podsadecki T., Bernstein B. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N. Engl. J Med. 2014; 370: 1973-82.
  14. Feld J.J., Moreno C., Trinh R., Tam E., Bourgeois S., Horsmans Y., Elkhashab M., Bernstein D.E., Younes Z., Reindollar R.W., Larsen L., Fu B., Howieson K., Polepally A.R., Pangerl A., Shulman N.S., Poordad F. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. Hepatology 2016; 64(2): 301-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies